Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Equity Forum Spring Conference 2024
18 slides from Marinomed Biotech's conference presentation, May 14, 2024
Slide 1: Investor Presentation
Investor Presentation Equity Forum Spring Conference May 14-15, 2024
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Equity Story
Equity Story Solid existing business, growth perspective through late-stage pipeline assets Experienced management team Recurring revenue from marketed products Andreas Eva Prieschl- Pascal Grassauer Grassauer Schmidt Chief Executive Chief Scientific Chief Financial Late-stage assets in partnering O
Slide 4: Marinomed at a glance
Marinomed at a glance Publicly listed biopharmaceutical company located in Korneuburg, Austria 15 Revenue, EBIT and R&D spending (€m) 11.6 11.3 9.2 Revenue 10 8.1 * * 6.1 ** EBIT * 5 R&D expenses 0 * Revenue driven by pandemic impact -5 ** Including € 1.9m -4.1 -4.9 milestone -4.8 -5.8 -5.1 -6.2 -6.
Slide 5: Business Model
Business Model Development phase OTC (over-the-counter) Rx (prescription) Idea & preclinical research Generation of Early clinical development intellectual property Late clinical development Market authorization Manufacturing Commercialization Distribution & marketing through partners Vigilance Mari
Slide 6: Technologies & Therapeutic Areas
Technologies & Therapeutic Areas Universal blocking of viruses and allergens as well as Solubilization of poorly water-soluble compounds and moistening of mucosal tissues improving local onset of action Cough & cold Allergy Eye drops Budesolv Tacrosolv Solv4U portfolio* nasal spray* Dry, irritated A
Slide 7: Pipeline
Pipeline Including late-stage projects with low risk and meaningful upside potential Pharmaceutical Products Therapeutic Product Status Pre-clinical Phase I Phase II Phase III Filing Area Indication MAM-1004-1/Budesolv Filing in Treatment of severe allergic rhinitis preparation IMMUNOLOGY MAM-1003-1
Slide 8: Carragelose
Carragelose Universal blocking of viruses and allergens as well as moistening of mucosal tissues Recent developments • Expansion of product portfolio in Immunology with allergen blocker and eye drops • New distribution partnerships for Gulf region Without Carragelose: With Carragelose: and Eastern E
Slide 9: Marinosolv
Marinosolv Solubilization of poorly water-soluble compounds - improving local onset of action Recent developments • MAM-1004-1/Budesolv • Innovation in formulation & primary packaging → improved stability • BD process gaining momentum Aqueous formulation of hardly Marinosolv formulation of • Partner
Slide 10: Solv4U overview
Solv4U overview Solubilization technology partnerships based on Marinosolv® PHASE I PHASE II PHASE III PHASE IV FEASIBILITY FORMULATION PRECLINICAL & TECH TRANSFER DEVELOPMENT CLINICAL STUDIES Enhanced solubility of target Optimize formulation & Target Product Profile (TPP) & Enable manufacturing at
Slide 11: FY 2023 revenue in line with post-pandemic market
FY 2023 revenue in line with post-pandemic market High customer stock-levels lead to slow order intake Y-o-Y comparison of quarterly revenues (m€) Comments Historical numbers 11.3 9.2 • Revenues expectedly declined to €9.2m (previous year €11.3m) • Revenues largely related to Carragelose product por
Slide 12: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) Higher revenues – increased R&D expenses 1 FY 2023 FY 2022 €m FY 2023 FY 2022 Sale of goods 8.1 10.5 Revenues 1 9.2 11.3 Cost of goods sold -5.8 -7.1 Margin 29.0% 32.3% Other income 2 1.4 0.8 Materials expenses -5.9 -7.3 •2 Primarily consisting of research premium
Slide 13: Stabilized cash situation
Stabilized cash situation Low cash drain due to Carragelose revenues and inflows from convertible bond program • Ended December 2022 with €8.2m in cash (as a result of the €6.0m EIB tranche 3 draw down) • Raised +€0.5m through convertible note funding program • Earned +€3.2m net cash through profita
Slide 14: Deferral of EIB repayments by 18 months
Deferral of EIB repayments by 18 months Real estate lenders also agreed to suspension Tranche I Tranche II Tranche III EUR 4 million EUR 5 million EUR 4.7 million Outstanding nominal Outstanding nominal Outstanding nominal October 2024 → April 2026 December 2025 → June 2027 December 2025 - August 20
Slide 15: Summary project status (May 2024)
Summary project status (May 2024) Project Status/next steps MAM-1001-4 nasal spray Launched in Austria; drive BD-process for further partnerships Immunology MAM-1001-3 eye drops Complete clinical study in Spain and launch in 2024; drive BD-process MAM-1004-1/Budesolv Additional partnerships in 2024;
Slide 16: Translating innovation into top-line growth
Translating innovation into top-line growth Biotech business model with high upside potential Maximize Conclude Support Luoxin First Expand Solv4U value of further license towards next partnership for technology Carragelose agreements milestone Tacrosolv partnerships business for Budesolv Focus on g
Slide 17: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar 2024 May 22, 2024 Publication of the Results Q1 2024 Record Date for participation June 10, 2024 at the Annual General Meeting June 20, 2024 7th Annual General Meeting August 20, 2024 Publication of the Results H1 2024 November 21, 2024 Publication
Slide 18: www.marinomed.com
www.marinomed.com Q? Marinomed
Marinomed Biotech — Equity Forum Spring Conference 2024 on 6ix